GEMALTO

6.3.2019 07:02:16 CET | Business Wire | Press release

Gemalto Expands Cloud HSM On Demand Solutions

Gemalto, the world leader in digital security, today announced the availability of three new cloud-based Hardware Security Module (HSM) services, HSM On Demand for CyberArk , HSM On Demand for Hyperledger and HSM On Demand for Oracle TDE . Each service is available through the SafeNet Data Protection on Demand platform, a marketplace of cloud-based HSM, encryption and key management services that easily integrates with most widely used cloud services and IT products to protect data wherever it is created, accessed or stored.

The rapid adoption of cloud and digital services has made it difficult for organizations to secure data and identities that are created, stored and managed outside the perimeter. While organizations recognize that data encryption is the optimal solution to secure sensitive information, they can be challenged by the cost and complexity of deploying encryption, including Hardware Security Modules to secure their cryptographic operations. Gemalto’s SafeNet Data Protection On Demand solves these challenges by providing cloud-based HSM services that and can be deployed in minutes without the need for highly skilled staff. Gemalto, a leader in the HSM market, is proven to help customers secure their encryption keys and data across cloud, hybrid, and on-premises environments.

“A worsening threat landscape, combined with aggressive cloud adoption and evolving privacy regulations, have presented complex new challenges related to encryption, privileged access and financial transactions,” said Todd Moore, Senior Vice President of Encryption Products at Gemalto. “Our newest Cloud HSM On Demand services help organizations stay in front of new threats and regulations, by easily deploying an HSM solution for the strongest possible key management and security practices, all while providing fast, easy set-up, with remarkable savings over traditional approaches involving specialized hardware and skills.”

“Many organizations would like to deploy data security more broadly, but are often wary due to concerns about complexity, cost and staffing requirements, particularly with respect to encryption and key management,” said Garrett Bekker, Principal Analyst at 451 Research. “The release of SafeNet Data Protection On Demand was a positive step towards addressing those concerns, and extending its cloud HSM capability to newer use cases like blockchain, database security and privileged credentials is a logical and timely move.”

HSM On Demand for CyberArk
HSM On Demand for CyberArk works seamlessly with CyberArk’s Privileged Access Security Solution, providing private key protection and strong entropy for key generation for system keys.. By securing the master key and ensuring that it is hosted in a secure vault, HSM On Demand for CyberArk mitigates the risk of the master key being exposed or compromised.

HSM On Demand for Hyperledger
HSM On Demand for Hyperledger provides trust for blockchain transactions by securing the cryptographic keys that sign them. It protects digital wallets, while ensuring keys are readily available in the cloud once access is granted. The service provides high assurance security in data centers and the cloud, enabling multi-tenancy of blockchain identities per partition as proof of transaction and for auditing requirements. It also delivers performance improvements resulting from off-loading cryptographic operations from application servers to the HSM on Demand service.

HSM On Demand for Oracle TDE
HSM for Oracle TDE (Transparent Data Encryption) solves the challenge presented by locally stored encryption keys by protecting them with a master key, stored in a separate service key vault. This ensures that only authorized services are allowed to request the local key to be decrypted. If an attacker steals the database, it is encrypted and inaccessible, since the attacker does not have access to the keys that are securely stored on the HSM.

Additional Resources

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2018 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.

From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.

Our 15,000 employees operate out of 110 offices, 47 personalization and data centers, and 35 research and software development centers located in 47 countries.

For more information visit www.gemalto.com , or follow @gemalto on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005648/en/

Contact:

Gemalto media contacts: Tauri Cox North America +1 512 257 3916 tauri.cox@gemalto.com

Sophie Dombres Europe Middle East & Africa +33 4 42 36 57 38 sophie.dombres@gemalto.com

Jaslin Huang Asia Pacific +65 6317 3005 jaslin.huang@gemalto.com

Alexis Camarillo Latin America +52 5521223627 alexis.camarillo@gemalto.com

Link:

ClickThru

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom